Latest Breaking News On - Alexandre abizaid - Page 1 : vimarsana.com

Elixir Medical s Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World s First Site-Specific Antithrombotic Therapeutic Compared to DES

DESyne BDS Plus system with site-specific antithrombotic therapeutic (TRx) significantly reduced the risk of TLF versus conventional drug-eluting stent through 12-months

New zealandSao pauloFrance generalUnited statesAlexandran nowbarJamesp howardMichael foleyKui hongMotasim sirhanXiaoqing liLiza chackoDarrelp francisDina mahdiSayan senAlexandre abizaidGraham cole

Elixir Medical Corporation: EuroPCR 2024: Elixir Medical s Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World s First Site-Specific Antithrombotic Therapeutic Compared to DES

Elixir Medical Corporation: EuroPCR 2024: Elixir Medical s Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World s First Site-Specific Antithrombotic Therapeutic Compared to DES
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

France generalSao pauloNew zealandUnited statesLiza chackoAlexandre abizaidYuhao suKui hongChristopher rajkumarXiaoqing liJamesp howardRasha al lameeSayan senEmma yangYousif ahmadGraham cole

Supira Medical s Next Generation Percutaneous Ventricular Assist Device (pVAD) System to be Highlighted in a Live Case and Multiple Sessions at TCT23

Supira's technology features a novel low profile, high continuous flow design that aims to provide full hemodynamic support for high-risk percutaneous coronary interventions (HRPCI) and cardiogenic shock (CS) patients with a single device

Carlos camposSan franciscoUnited statesNitin salunkeFabios brito jrAlexandre abizaidGagan singhAzeem latibStructural heart interventions at montefiore health systemsMedtech innovation forumSupira medical incSupira medicalCardiovascular therapeuticsSupira systemTemporary mechanical circulatory supportBalancing clinical needs

Supira Medical s Next Generation Percutaneous Ventricular Assist Device (pVAD) System to be Highlighted in a Live Case and Multiple Sessions at the Upcoming TCT 2023 Conference

/PRNewswire/ Supira Medical, Inc., a Shifamed portfolio company, announced today that the company s percutaneous ventricular assist device (pVAD) will be.

San franciscoUnited statesCarlos camposAlexandre abizaidNitin salunkeKatie arnoldGagan singhAzeem latibFabios brito jrAmr salahiehPrnewswire supira medical incMedtech innovation forumSupira medical incStructural heart interventions at montefiore health systemsCardiovascular therapeuticsSupira system

TCT23 Late-breakers: Full Schedule Announced

Late-breaking trials will be presented during the main sessions and highlighted during press conferences scheduled for Oct. 24, 25 and 26

United statesSan franciscoSuzannev arnoldDavide kandzariRobertl smithDavidh adamsAmitn voraSusheelk kodaliJoanna chikweSuzannej baronFiras zahrAnitaw asgarTobias kochMirvat alasnagRoberto bonowRobertw yeh